American Diabetes Association

Sue Kirkman, MD, professor of medicine at UNC Chapel Hill, discusses the results of a study she led that attempted to create a method of identifying what type of diabetes through EHR data.

John Buse, MD, professor of medicine at UNC Chapel Hill, discusses the results and implications of the PIONEER 7 trial.

It's been 5 years since the FDA approved empagliflozin, and 4 since the major outcomes findings. What is its role in diabetes care today?

The three-year trial reported that initial weight loss plus 1 of any 4 diet and exercise programs is associated with major benefits for at-risk patients.

A review of REDUCE-IT data prior to an FDA supplemental new drug application decision shows the unprecedented benefit of the fish oil therapy.

Todd Hobbs, MD, chief medical officer of Novo Nordisk North America, discusses the results of PIONEER 4 at ADA 2019 in San Francisco, CA.

Todd Hobbs, MD, chief medical officer at Novo Nordisk North America, discusses what prompted Novo Nordisk to create oral semaglutide.

Todd Hobbs, MD, CMO of Novo Nordisk, discusses the findings of the PIONEER 2 study.

New findings show the controversial 2018 blood sugar control recommendations are associated with cost benefits for 3 subgroups of affected T2D patients.

A new study which considered the suggested association between type 2 diabetes and vitamin D deficiency did not show a statistically significant reduction of patient risk.

Peter Toth, MD, spoke about the importance of noting elevated triglycerides in patients at risk for cardiovascular conditions.

The study revealed for the first time that triglycerides can be utilized as an independent predictor of cardiovascular risk—a landmark moment.

The poster presentations included a meta-analysis of 17 studies analyzing the cost-effectiveness and performance of the CGM system and a real-world examination of the trends its use.

Tim Dunn, PhD, discussed the benefits that the Freestyle Libre continuous glucose monitoring system provides for both the patients and providers

In a comparison of canagliflozin to other SGLT-2 inhibitors and anti-hyperglycemic therapies, the drug was found to decrease hospitalization from heart failure risk, and carry no extra risk for leg or foot amputation.

Murray Stewart, MD, spoke about his research into the hormone leptin—a major player in appetite and metabolism, with much that's still misunderstood about it.

The addition of features such as Bluetooth and Wi-Fi connectivity, in addition to cloud-to-cloud integration, is essential to improving diabetes devices.

Across the 6-month duration of the trial, weight loss was maintained across all dose levels, with patients that had the lowest baseline leptin levels benefitting the most.

How telehealth-friendly devices could change standard of diabetes care — with the help of physicians, patients, and the overall health care system.

Patients spent 11.2% more time in their target glucose range, and hypoglycemia was reduced from 5.1% to 1.9% overall, and 5.7% to 0.7% overnight.

How some of the most recent trial analysis narrows the clinical scope of GLP-1 and SGLT-2 targeting therapies.

Grenye O'Malley, MD, spoke about study data on insulin pen priming for patients with type 1 diabetes, noting that 80% of patients reported priming frequently.

Cardiovascular disease is the leading cause of death in women. And yet, the crux of concern for disease risk is designated to male patients.

Is there a relationship between polycystic ovary syndrome and diabetes? And if so, what are the variations in female patients?

The OPTIFAST meal replacement program resulted in better outcomes than the standard of care and a higher proportion of patients no longer meeting criteria for type 2 diabetes.

During the first 12 weeks of study, the investigated therapy had also reduced patient hypoglycemia event rates by 23% and low blood sugar event rates by 26% versus comparative therapy.

Despite several of these 2 medicines have proved to reduce cardiovascular risks, that has not been the case for all options, leading to confusion.

The Medtronic MiniMed 670G system was expanded for pediatric T1D patients, then reported positive real-world symptom management during ADA 2018.

Though the rate of suicidal ideation in pediatric patients with T1D is not significant from general population, girls reported twice as frequent rates.

Empagliflozin has reported positive outcomes in renal conditions and heart failure in T2D patients. Now what?